Boston, MA – February 15, 2013 – Susan Bonner-Weir, Ph.D., Senior Investigator in the Section on Islet Cell & Regenerative Biology at the Joslin Diabetes Center and Professor of Medicine at Harvard Medical School has been named a Fellow of the American Association for the Advancement of Science (AAAS).
Election as an AAAS Fellow is an honor bestowed upon AAAS members by their peers and is awarded on the basis of their scientifically or socially distinguished efforts to advance science or its applications. Dr. Bonner-Weir is being honored for her major contributions in the areas of architecture and function of the islet, in vivo regulation of β-cell mass, and islet growth and differentiation.
According to George King, M.D., Chief Scientific Officer at Joslin, "Dr. Bonner-Weir has provided landmark contributions to the understanding on the changes in pancreatic beta cells with diabetes. Her collegial reputation on collaboration is well known and has helped to propel this field greatly."
"This is such an honor," said Dr. Bonner-Weir. "I've had enormous pleasure delving in the fascinating science of the pancreatic beta cell, which hopefully will lead to help for people with diabetes."
Formal presentation of the award will be made during the AAAS Fellows Forum at the 2013 AAAS Annual Meeting, September 16, in Boston, MA.
About Joslin Diabetes Center
Joslin Diabetes Center, located in Boston, Massachusetts, is the world's largest diabetes research and clinical care organization. Joslin is dedicated to ensuring that people with diabetes live long, healthy lives and offers real hope and progress toward diabetes prevention and a cure. Joslin is an independent, nonprofit institution affiliated with Harvard Medical School.
Our mission is to prevent, treat and cure diabetes. Our vision is a world free of diabetes and its complications. For more information, visit www.joslin.org.
About Joslin Research
Joslin Research comprises the most comprehensive and productive effort in diabetes research under one roof anywhere in the world. With 30‐plus faculty level investigators and an annual research budget of $36 million, Joslin researchers focus on unraveling the biological, biochemical and genetic processes that underlie the development of type 1 and type 2 diabetes and related complications.
Joslin research is highly innovative and imaginative, employing the newest tools in genetics, genomics and proteomics to identify abnormalities that may play a role in the development of diabetes and its complications. Joslin Clinic patients, and others with diabetes, have the option of participating in clinical trials at Joslin to help translate basic research into treatment innovations.
Joslin has one of the largest diabetes training programs in the world, educating 150 M.D. and Ph.D. researchers each year, many of whom go on to head diabetes initiatives at leading institutions all over the globe. For more information, visit www.joslinresearch.org.
About the AAAS Fellows Program
The tradition of AAAS Fellows began in 1874. Currently, members can be considered for the rank of Fellow if nominated by the steering groups of the Association's 24 sections, or by any three Fellows who are current AAAS members (so long as two of the three sponsors are not affiliated with the nominee's institution), or by the AAAS chief executive officer.
Each steering group then reviews the nominations of individuals within its respective section and a final list is forwarded to the AAAS Council, which votes on the aggregate list.
The Council is the policymaking body of the Association, chaired by the AAAS president, and consisting of the members of the board of directors, the retiring section chairs, delegates from each electorate and each regional division, and two delegates from the National Association of Academies of Science.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.